Show simple item record

dc.contributor.authorSebastian, M
dc.contributor.authorBarlesi, F
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorMansfield, AS
dc.contributor.authorBlackhall, FH
dc.contributor.authorFlahavan, EM
dc.contributor.authorDavies, J
dc.contributor.authorArnold, P
dc.contributor.authorMorris, S
dc.contributor.authorReck, M
dc.date.accessioned2019-10-04T09:48:29Z
dc.date.available2019-10-04T09:48:29Z
dc.date.issued2019en
dc.identifier.citationSebastian M, Barlesi F, Califano R, Mansfield AS, Blackhall FH, Flahavan EM, et al. 66PTreatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice. Ann Oncol. 2019;30(Supplement_2).en
dc.identifier.doi10.1093/annonc/mdz071.006en
dc.identifier.urihttp://hdl.handle.net/10541/622140
dc.description.abstractBackground For pts with ES-SCLC, guidelines recommend carbo or cis + etop as first-line (1L) tx. However, real-world data (RWD) on tx patterns and outcomes are limited. Here, we describe pt characteristics, tx duration and clinical outcomes associated with these 2 regimens. Methods Pts with ES-SCLC diagnosis (or limited-stage [LS] SCLC who initiated second-line [2L] tx) between 1 Jan 2013 and 31 Aug 2017 (follow-up to 31 Aug 2018) were identified from the US-based Flatiron Health electronic health record–derived database. Pts receiving tx with either carbo + etop or cis + etop were included in the analysis. Results RWD on 2161 pts from 156 tx centres were included; 84% of pts received carbo + etop. See table below for pt characteristics. The median tx duration was 3.4?mo (95% CI: 3.4, 3.4) with carbo + etop and 3.0?mo (95% CI: 2.8, 3.4) with cis + etop. The distribution of tx cycles administered was similar between carbo and cis, with 20% and 28% of pts completing 4 or 6 cycles, respectively. Median overall survival (OS) was 8.3?mo (95% CI: 8.1, 8.7) with carbo + etop and 9.7?mo (95% CI: 9.3, 11.0) with cis + etop. The 1-yr OS rates were 30% (95% CI: 28, 33) and 41% (95% CI: 36, 47), respectively. In pts with Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 and ? 2, median OS was 9.3?mo (95% CI: 8.6, 9.9) and 7.1?mo (95% CI: 6.3, 8.3), respectively. Pts with unknown ECOG PS had a median OS of 8.4?mo (95% CI: 8.0, 8.9). Conclusions Tx duration was similar between the 2 regimens. Pts who received cis + etop had numerically increased OS vs pts who received carbo + etop, as did pts with ECOG PS 0-1. However, these findings may be due to pts receiving cis + etop being fitter (younger and lower ECOG PS) at baseline.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz071.006en
dc.titleTreatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practiceen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversitatsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Mainen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T13:33:34Z


Files in this item

Thumbnail
Name:
562034.pdf
Size:
66.02Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record